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C1q-Mediated Repression of Human Monocytes Is Regulated
by Leukocyte-Associated Ig-Like Receptor 1 (LAIR-1)
Myoungsun Son and Betty Diamond
Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, New York, United States
of America

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by abnormal function of both the innate
and the adaptive immune system, leading to a loss of tolerance to self-antigens. Monocytes are a key component of the innate immune system and are efficient producers of multiple cytokines. In SLE, inappropriate activation of monocytes is thought
to contribute to the loss of self-tolerance. In this study, we demonstrate that type 1 interferon (IFN) production by CpGchallenged monocytes can be suppressed by C1q through activating leukocyte-associated Ig-like receptor-1 (LAIR-1), which
contains immunoreceptor tyrosine-based inhibition motifs (ITIMs). The phosphorylation of LAIR-1 and the interaction of LAIR-1
with SH2 domain–containing protein tyrosine phosphatase-1 (SHP-1) were enhanced after LAIR-1 engagement by C1q. Moreover, engagement of LAIR-1 by C1q inhibited nuclear translocation of interferon regulatory factor (IRF)-3 and IRF5 in CpGstimulated monocytes. These data suggest a model in which LAIR-1 engagement by C1q helps maintain monocyte tolerance,
specifically with respect to Toll-like receptor-9–mediated monocyte activation.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2014.00185

INTRODUCTION
Early studies on the pathogenesis of
systemic lupus erythematosus (SLE) focused on the adaptive immune system,
since B and T lymphocyte abnormalities
were thought to be the primary cause of
autoimmunity. However, it is now increasingly recognized that components
of the innate immune system also play
an essential role in SLE (1–5).
Monocytes are myeloid cells that play
a key role in innate immunity and are efficient producers of proinflammatory cytokines and type 1 interferons (IFNs),
IFNα and IFNβ, when stimulated by
pathogen-associated molecular patterns
(PAMPs) such as unmethylated bacterial
DNA or damage-associated molecular

patterns (DAMPs) such as apoptotic debris (2,5,6). Numerous monocyte defects
involving aberrant activation and dysregulation of cytokine production have
been identified in SLE patients (1,3). Notably, increased levels of type 1 IFN are
seen in virtually all pediatric patients
and a substantial percentage of adult patients. High IFN levels are a feature of
some unaffected first-degree relatives as
well (7,8).
TLR9, expressed by B cells, macrophages, monocytes, dendritic cells (DCs)
and plasmacytoid DCs (pDCs), recognizes CpG, which mimics bacterial DNA
(9–13). CpG 2216 is a prototype of the
class of CpG (CPG-A), which preferentially activates myeloid cells as opposed

Address correspondence to Betty Diamond, Center for Autoimmune and Musculoskeletal
Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY
11030. Phone: 516-562-3830; Fax: 516-562-2953; E-mail: bdiamond@nshs.edu.
Submitted September 15, 2014; Accepted for publication September 17, 2014; Epub
(www.molmed.org) ahead of print September 17, 2014.

to B cells (14). Human monocytes exposed to CpG-A can differentiate into
DCs and produce a number of cytokines
including interleukin (IL)-6, IL-12, tumor
necrosis factor (TNF)-α and type I IFN
(15). When TLR9 associates with CpG
motifs in the endosome, it recruits
MyD88; the TLR9/MyD88 complex leads
to activation of interferon regulatory factors (IRFs) (16,17). IRFs including IRF3,
IRF5 and IRF7 are phosphorylated and
translocate into the nucleus, where they
regulate transcription of type 1 IFN
mRNA. IRF3 and IRF8 cooperatively regulate IFNβ production in monocytes
stimulated with TLR ligands such as LPS
(TLR4), Pam3csk4 (TLR2) or viral infection (18), whereas IRF3 cooperates with
IRF7 to regulate IFNβ production in
pDCs on TLR9 stimulation (19). Secreted
type 1 IFNs bind to the IFN receptor
(IFNR) acting in an autocrine manner to
induce the expression of a set of secondary IFN response genes (IFN signature
genes [ISGs]) such as Mx1 and OAS1
(20). Expression of these genes is tightly
regulated by type 1 IFNs through the
consensus IFN-stimulated response elements (20,21). IRF5 also regulates tran-
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scription of the proinflammatory cytokines IL-6 and TNFα (22); IRF5 and nuclear factor (NF)-κB p50 coregulate IL-6
in TLR9-stimulated human plasmacytoid
DCs (pDCs) (23). Genetic polymorphisms of IRF3, IRF5 and IRF7 have been
associated with susceptibility to SLE
(17,24) and elevated levels of nuclear
IRF5 have been demonstrated in monocytes of SLE patients (4).
A Src family kinase (SFK)-driven tyrosine phosphorylation pathway at the
plasma membrane is upstream of and required for TLR9/MyD88 activation in
endosomes (12). This result suggests that
a potential CpG-sensing receptor is localized at the plasma membrane and may
activate SFKs. Two SFKs, Hck and Lyn,
are phosphorylated in monocytes after
stimulation by CpG and induce actin cytoskeleton reorganization. They also activate the TLR9/MyD88 signaling cascade
(12). The activation of SFKs is implemented through the catalytic activity of
the kinase domain and through proteinprotein interactions of the regulatory
SH2 and SH3 domains (25,26). Regulation of SFKs is modulated by C-Src kinase (Csk), which phosphorylates the
C-terminal tyrosine of SFK, resulting in a
catalytically inactive conformation (27).
Although much is understood regarding
the production of IFN downstream of
TLR9, the membrane proximal molecular
events that suppress these pathways to
prevent overproduction of cytokines
have not been well described.
Leukocyte-associated Ig-like receptor-1
(LAIR-1) is an inhibitory immune receptor with immunoreceptor tyrosine-based
inhibition motifs (ITIMs). It is expressed
on human myeloid and lymphoid cells,
including NK cells, T cells, B cells and
monocytes; monocyte-derived DCs; and
CD34+ hematopoietic progenitor cells
(28–32). LAIR-1 engagement inhibits the
differentiation of peripheral blood precursors into DCs (33,34). On antibodymediated cross-linking, the tyrosines in
the ITIMs of LAIR-1 become phosphorylated; phosphorylation of both ITIMs is
required for full inhibition of cellular activation (30,35). Phosphorylation of

LAIR-1 is inhibited by PP2, a SFK inhibitor, suggesting that the kinase responsible for LAIR-1 phosphorylation is
an SFK such as Lck, Hck or Lyn (36).
Both human and mouse LAIR-1 are associated with Csk (30,35). Engagement of
LAIR-1 recruits SH2 domain–containing
protein tyrosine phosphatase-1 (SHP-1),
which negatively regulates intracellular
signaling (36). In NK cells, SHP-1 is associated with LAIR-1 upon stimulation by
monoclonal anti–LAIR-1 antibody (31).
Engagement of LAIR-1 by collagen recruits SHP-1, which negatively regulates
intracellular signaling (36). SHP-1 appears to be important for negative regulation of type 1 IFN production and consequent protection against SLE-like
inflammation (24,37).
The complement component C1q and
extracellular matrix collagens are functional ligands for LAIR-1 and directly inhibit immune cell activation (34,38,39).
C1q has been shown to regulate cytokine
production and MyD88-dependent TLRmediated signaling in murine bone
marrow–derived DCs (40) and to inhibit
IFNα production by human pDCs in
response to stimulation by TLR ligands
in vitro (34). Moreover, C1q deficiency
has been associated with abnormal
production of IFNα by pDCs in SLE
patients (41).
Here, we set out to define how C1q
suppresses CpG-mediated activation of
monocytes. First, we demonstrate that
CpG-induced production of type 1 IFN
by monocytes is suppressed by C1q or
anti–LAIR-1 monoclonal antibodies
(mAbs) and is characterized by less nuclear translocation of IRFs. C1q-mediated
suppression did not occur in cells transfected with LAIR-1 siRNA, confirming
the importance of LAIR-1 to this inhibitory pathway. CpG alone augmented
an interaction between LAIR-1 and the
inactive form of Hck. However, when
LAIR-1 was engaged by C1q or
anti–LAIR-1 antibody in CpG-stimulated
monocytes, the interaction between Hck
and LAIR-1 was abrogated, and an interaction between SHP-1 and LAIR-1 was
evident. Interestingly, we also found that
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LAIR-1 mediates a ligand-independent
suppression of cytokine production.
These findings demonstrate that C1q and
LAIR-1 are dynamically involved in
monocyte homeostasis.
MATERIALS AND METHODS
Reagents
Fluorochrome-conjugated and unconjugated antibodies were purchased:
phycoerythrin (PE)-labeled or unlabeled
mouse anti-human LAIR-1 (DX26; BD
Pharmingen [BD Biosciences, San Jose,
CA, USA]) for flow cytometry or stimulation; goat anti-human LAIR-1 (T-15,
Santa Cruz Biotechnology, Dallas, TX,
USA) for Western blotting; mouse
anti–SHP-1 (D-11, Santa Cruz Biotechnology); rabbit anti-Hck (Abcam, Cambridge, MA, USA); mouse anti–phosphoSrc (Invitrogen [Thermo Fisher Scientific
Inc., Waltham, MA, USA]); rabbit antiIRF3 (Cell Signaling Technology, Danvers, MA, USA); rabbit anti-IRF5 (Protein Tech, Chicago, IL, USA); mouse
anti–phospho-IkBα (Ser32/36; Cell Signaling Technology); mouse anti–phosphoIkBα (Cell Signaling Technology);
mouse anti–lamin A/C (Sigma-Aldrich,
St. Louis, MO, USA); mouse anti–β actin
(AC-15, Sigma-Aldrich); rabbit antiGAPDH (anti–glyceraldehyde-3phosphate dehydrogenase) (Cell Signaling Technology); anti-CD11b, anti-CD14
and isotype-matched control antibodies
(BD Pharmingen [BD Biosciences]); and
human Fc receptor blocking solution
(Biolegend, San Diego, CA, USA). Cell
culture reagents included the following:
Ficoll-plaque plus (GE Healthcare, London, UK); penicillin/streptomycin,
RPMI 1640, L-glutamine and HEPES (all
from Gibco/Invitrogen [Thermo Fisher
Scientific]); heat-inactivated fetal bovine
serum (FBS) (Hyclone, Logan, UT,
USA); and X-VIVO serum-free media
(Lonza, Basel, Switzerland). Other
reagents used included: C1q from Complement Technology (Tyler, TX, USA);
CpG 2216 (Invitrogen [Thermo Fisher
Scientific]); 1× RIPA cell lysis buffer (Invitrogen [Thermo Fisher Scientific]);
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protease inhibitor cocktail (Pierce,
Waltham, MA, USA); phosphatase inhibitors (Pierce); formaldehyde, Triton
X-100 and NP-40 (Sigma-Aldrich);
Tween-20 (Fisher Scientific [Thermo
Fisher Scientific]); and phosphatebuffered saline (PBS) and distilled water
(Gibco/Invitrogen [Thermo Fisher Scientific]). Proteins and culture reagents
were endotoxin-tested (<0.1 Endotoxin
Units [EU]/mL) either by the manufacturer or by using a limulus amebocyte
lysate assay kit performed per the manufacturer’s instructions (Charles River
Endosafe, Kingston, NY, USA).
Human Monocyte Isolation, Culture
and Stimulation
Human peripheral blood mononuclear
cells (PBMCs), obtained according to institutional guidelines of the Feinstein Institute for Medical Research, were isolated from the blood of healthy donors
by density centrifugation (New York
Blood Center, New York, NY, USA).
Monocytes were negatively enriched by
using a human monocyte enrichment kit
(Stemcell Technologies, Vancouver, BC,
Canada). Purity of monocytes (~90%
CD11b+ CD14+) was assayed by flow cytometry. Purified monocytes (1 × 106
cells/mL) were immediately stimulated
for indicated times until 30 min with
CpG 2216 (5 μmol/L), C1q (25 μg/mL)
or anti–LAIR-1 antibody (10 μg/mL) in
X-VIVO serum-free medium and harvested at the indicated time points. For
cytokine assay, cells were cultured in
U-bottom 96-well plates (Nunc,
Waltham, MA, USA) containing complete media (RPMI-1640 containing
2 mmol/L L-glutamine, 10 mmol/L
HEPES, 50 IU/mL penicillin, 50 mg/mL
streptomycin and 10% FBS).
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was extracted with an
RNeasy kit (Qiagen, Hilden, Germany)
and subjected to reverse transcription
with an iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). cDNA was analyzed by quantitative polymerase chain

reaction (qPCR) by using a LightCycler
480 master mix with TaqMan probes
(Applied Biosystems [Thermo Fisher
Scientific]) against human IFNα4
(Hs01681284), IFNβ1 (Hs01077958), MX1
(Hs00182073), OAS1 (Hs00242942), IL-6
(Hs00985639), TNFα (Hs00174128) and
Polr2A (Hs00172187). Data were normalized to Polr2a; relative induction was calculated by ΔΔCt.
Cytokine Assay
Cytokine analysis for IL-6 and TNFα
was performed using a Human ProInflammatory 7-Plex Ultra-Sensitive Kit
(Meso Scale Discovery [MSD], Rockville,
MD). MSD plates were analyzed on the
MS2400 imager (MSD). Assay was performed according to the manufacturer’s
instructions. All standards and samples
were measured in duplicate.
Isolation of Nuclear Fractions
The NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Scientific
[Thermo Fisher Scientific]) was used for
nuclear extraction following the manufacturer’s protocol. The efficiency of nuclear fractions was determined by immunoblotting for lamin.
Confocal Microscopy
Unstimulated or stimulated monocytes
were washed three times with ice-cold
PBS, fixed with 4% (v/v) paraformaldehyde and permeablized with 0.2% Triton
X-100. Cells were seeded (2 × 105 cells/mL)
on slides by using cytospin and blocked
with 2% goat serum and 2% bovine
serum albumin (Invitrogen [Thermo
Fisher Scientific]). Cells were incubated
overnight at 4°C with anti-IRF3 antibody
(1:100) and washed and incubated with
Alexa Fluor 488–labeled goat anti-mouse
antibody (1:200; Invitrogen [Thermo
Fisher Scientific]). Nuclei were stained
with propidium iodide (0.5 μg/mL;
Sigma-Aldrich). Cells were washed and
mounted, and confocal images were captured by FluoView 300 (Olympus, Center
Valley, PA, USA) and analyzed by using
Axio vision 4.8 software (Zeiss, Jena,
Germany).

Transfection and Flow Cytometry
In RNA interference assays, monocytes
were transfected by using an AmaxaNucleofector kit (Lonza). Transfection efficiency was over 40%. siRNAs for LAIR-1
or control siRNA were from Qiagen. The
target sequence of human LAIR-1 is
CAGCATCCAGAAGGTTCGTTA. The
efficiency of knockdown was determined
by flow cytometry (FACS verse; BD Biosciences) with PE-labeled anti-human
LAIR-1 antibody. Data were analyzed by
using FlowJo software (Tree Star; see
http://www.flowjo.com/).
Immunoprecipitation and Western Blot
Analysis
Unstimulated or CpG-stimulated
monocytes (2–5 × 106 cells/mL) were
washed in ice-cold PBS and lysed in 1×
RIPA buffer containing complete protease inhibitor mixture (Roche, Basel,
Switzerland) and phosphatase inhibitor
(Pierce). For immunoprecipitation, cell
lysates were then diluted 10-fold with
lysis buffer and anti–LAIR-1 antibody
before being incubated with precleared
protein G-dynabeads (Life Technologies
[Thermo Fisher Scientific]). Immunoblotting of bound proteins was performed
with the indicated antibodies.
Phospho-Immunoreceptor Array
To determine tyrosine phosphorylated
LAIR-1, cell lysates from monocytes (7 ×
106) stimulated without CpG or with
CpG only, CpG plus C1q or CpG plus
anti–LAIR-1 antibody were incubated
with human phosphoimmunoreceptor
array membranes (Proteome Profiler
Array; R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s
protocol. Phosphorylation levels of individual analytes were determined by average pixel density of duplicate spots; values were obtained after subtraction of
background and were normalized to positive control spots.
Statistical Analysis
Statistical analyses were performed
with Prism 5.0 (GraphPad, La Jolla, CA,
USA). P values were calculated by using
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Figure 1. LAIR-1 engagement by C1q or anti–LAIR-1 suppresses CpG-triggered production of cytokines in human monocytes. Purified
human monocytes from healthy donors were unstimulated or stimulated with CpGODN 2216 (CpG), C1q with CpG or anti–LAIR-1 antibody with CpG for 4 h. Transcripts were determined by qRT-PCR. C1q or anti–LAIR-1 antibody inhibited CpG-mediated IFNα and IFNβ induction (A), IFN signature genes MX1 and OAS1 (B) and CpG-mediated IL-6 and TNFα induction (C). (D) After 24 h of culture, supernatants were collected, and the production of IL-6 and TNFα was measured by MSD assay. Utx, untreated. R.E., relative expression. Results
represent the means ± standard error of the mean (SEM); the data were obtained from three independent experiments. *P < 0.05, **P <
0.01, ***P < 0.001.

a two-tailed unpaired Student t test or
two-way ANOVA. P values of <0.05 were
considered significant: *p < 0.05, **p <
0.01 and ***p ≤ 0.001 (Student t test).
RESULTS
C1q and LAIR-1 Modulate the
Expression of Multiple Genes in
Human Monocytes Stimulated with
CpG
We have previously shown that the addition of C1q to human pDCs inhibited
IFNα production after CpG stimulation
in a dose-dependent fashion. In addition,
this inhibition was reversed by soluble
LAIR-2 (34), suggesting that the inhibitory effects of C1q required that C1q
bind to LAIR-1. Besides pDCs, human
monocytes also highly express LAIR-1
and are efficient producers of type 1 IFN

and NF-κB–dependent cytokines after
TLR9 ligation. We examined a potential
role of the LAIR-1 signaling cascade activated by C1q or anti–LAIR-1 mAb in
regulating the expression of type 1 IFNs
(IFNα and IFNβ) and the ISGs MX1 and
OAS1 in human monocytes. We stimulated monocytes in serum-free medium
lacking C1q, with CpG ODN 2216, which
activates TLR9 (14). Significantly, IFN
and ISGs were induced by 4 h after CpG
stimulation, but not after C1q stimulation alone. Stimulation with CpG together with C1q led to diminished transcription of IFN and downstream ISGs
(Figures 1A, B). The proinflammatory cytokines IL-6 and TNFα were also induced by CpG exposure and inhibited at
the mRNA and protein level in the presence of C1q (Figures 1C, D). Anti–LAIR-1
antibody added to CpG-stimulated cells,
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but not control mouse IgG, also inhibited
induction of IFN, ISGs and proinflammatory cytokines, suggesting that LAIR-1
engagement might be the mechanism for
C1q-induced suppression.
To confirm the importance of LAIR-1,
we used LAIR-1 siRNA to decrease
LAIR-1 expression (Figure 2C). While
cells transfected with control siRNA responded to CpG with increased expression of IFNα and showed an inhibition
of CpG activation in the presence of C1q
or anti–LAIR-1 antibody, cells transfected
with LAIR-1 siRNA exhibited a higher
basal level of IFNα transcription and less
inhibition by C1q or anti–LAIR-1 antibody. The fact that basal IFNα transcription was not increased in cells transfected with control siRNA suggests that
the increase in IFNα transcription present in LAIR-1 siRNA-transfected mono-
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Figure 2. C1q-meditated suppression of IFNα and TNFα production is reversed by LAIR-1 siRNA. (A, B) Human monocytes were transfected
with control siRNA or LAIR-1 siRNA. After 24 h, cells were stimulated with CpG, C1q, CpG plus C1q or CpG and anti–LAIR-1 antibody for 4 h.
Transcripts of IFNα and TNFα were determined by qRT-PCR. Results represent mean ± SEM; the data were obtained from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.0001, ns, not significant. Percent inhibition was calculated as based on qRT-PCR. (C) The efficiency of siRNA was determined at 24 h by flow cytometry with PE-labeled anti–LAIR-1 antibody.

cytes was not due to engagement of
TLRs by siRNA, but rather that LAIR-1
has a constitutive C1q-independent inhibitory function in monocytes. TNFα
transcription was increased by CpG
stimulation in monocytes transfected
with control siRNA and was inhibited by
C1q or anti–LAIR-1 antibody (Figure 2B).
Basal TNFα transcription was increased
in monocytes transfected with LAIR-1
siRNA, and there was no discernable increase on exposure to CpG; thus, there
was no inhibition by C1q or anti–LAIR-1
antibody (Figure 2B). The data indicate
that C1q and LAIR-1 have an important
regulatory function in controlling cytokine production in response to CpG
challenge in monocytes.
C1q and LAIR-1 Inhibit the Nuclear
Translocation of IRFs Mediated by
CpG Stimulation
Because the transcription of type 1
IFNs and ISGs is strongly regulated by
IRFs, we studied the activation of these
molecules after CpG stimulation of
human monocytes. We isolated nuclear
fractions from human monocytes that
had been stimulated with CpG, with or

without C1q or anti–LAIR-1 antibody.
CpG caused an increased nuclear localization of IRF3 and IRF5, which was
not seen in the presence of C1q or
anti–LAIR-1 antibody (Figure 3A). We
used confocal microscopy to confirm our
observations on the subcellular localization of IRF3. In unstimulated monocytes
or monocytes treated with C1q alone,
IRF3 localized to the cytoplasm. When
CpG was added to monocytes, almost all
detectable IRF3 was translocated to the
nucleus (Figure 3B). The effect of CpG on
IRF3 nuclear translocation was suppressed by coincubation with C1q or
anti–LAIR-1 antibody. Approximately
75% of cells retained cytoplasmic IRF3 in
the presence of C1q (Figure 3B). As
shown in Figure 3C, phosphorylation of
IkBα, which releases the cytoplasmic retention of NF-κB, was enhanced by CpG
stimulation and reduced after CpG stimulation in the presence of C1q or
anti–LAIR-1 antibody. These data suggest that C1q and LAIR-1 signaling negatively regulates the nuclear translocation
of the key transcription factors for cytokine gene activation. Nuclear IRFs bind
to responsive elements in the promoters

in type 1 IFN genes. Furthermore, IRFs
cooperate with NF-κB to induce proinflammatory cytokines. Thus, C1q mediates suppression of monocytes to produce cytokines through these two
important pathways.
LAIR-1 Sequesters the Inactive Hck
during CpG-Mediated Activation
While C1q Leads to SHP-1
Engagement with LAIR-1
We next asked how LAIR-1 negatively
regulates CpG-mediated activation of
monocytes. To determine which proteins might be associated with LAIR-1,
we performed coimmunoprecipitation
studies. We found that Csk is associated
with LAIR-1 in unstimulated monocytes, and this association is present
also in CpG-stimulated monocytes (Figure 4A). Because Csk is known to phosphorylate the inhibitory tyrosine of
SFKs, we tested for SFK phosphorylation at this site. We found that inactive
SFK was associated with LAIR-1 in the
resting state and following CpG exposure (Figure 4A). We observed Hck to be
the major binding partner for LAIR-1 in
both unstimulated and CpG-stimulated
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Figure 3. LAIR-1 engagement inhibits CpG-mediated nuclear translocation of IRFs and the activation of NF-κB. Human monocytes were stimulated with CpG, C1q or anti–LAIR-1 antibody for 3 h. Nuclear fractions were analyzed by Western blot for IRF5, IRF3 and lamin for a marker for
the nuclear fraction. C1q and anti–LAIR-1 antibody inhibit CpG-mediated nuclear translocation of IRF5 and IRF3 (A). Data are representative
of three independent experiments. (B) Stimulated cells were stained for IRF3 and propodium iodine (PI) as a nuclear marker. The percentage
of IRF3 nuclear translocation was assessed in more than 200 cells in three independent experiments, and representative images are shown.
All images were viewed at 120× magnification by using a FluoView 300 confocal microscope (Olympus). (C) Purified monocytes were stimulated with CpG or C1q together with CpG for the indicated times, and cell lysates were assayed for phosphorylated-IkBα by Western blotting. Phosphorylated IkBα was normalized to GAPDH. Experiments were repeated three times, and representative data are shown.

monocytes. When LAIR-1 was engaged
by C1q or anti–LAIR-1 antibody in CpGstimulated monocytes, the interaction between Hck and LAIR-1 was abrogated,
and an interaction between SHP-1 and
LAIR-1 was enhanced (Figure 4A).
To explore the dynamic interactions of
these proteins, we performed the same
coimmunoprecipitation study at different
time points after CpG stimulation in the
absence or presence of C1q (5, 15 and 30
min). The results of this analysis suggested that Csk constitutively binds to
LAIR-1. Hck binds to LAIR-1 and is inactivated, presumably by Csk, after CpG
stimulation. However, on engagement by
C1q, LAIR-1 changes binding partners
and associates with SHP-1 (Figure 4B).

Next we studied whether CpG stimulation or LAIR-1 engagement alters the
phosphorylation of LAIR-1. We previously reported that C1q, C1q collagen
tail or anti–LAIR-1 antibody each induce
phosphorylation of LAIR-1 (34). Here,
monocytes were stimulated with CpG,
CpG plus C1q or CpG plus anti–LAIR-1
antibody. There was detectable phosphorylation of LAIR-1 even in unstimulated
monocytes, perhaps accounting for the
constitutive inhibition mediated by
LAIR-1. CpG challenge modestly increased LAIR-1 phosphorylation,
whereas LAIR-1 engagement with C1q or
anti–LAIR-1 antibody strongly induced
LAIR-1 phosphorylation (Figure 5). Presumably, Hck is responsible for the phos-
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phorylation of LAIR-1 that occurs after
C1q binding.
DISCUSSION
In this study, we demonstrate a suppressive mechanism of C1q in human
monocytes. Monocytes have been increasingly recognized to play a role in
both the initiation and propagation of
SLE given their functions in phagocytosis and cytokine production (1,5,6,42). In
particular, in the pristane-induced model
of murine lupus, monocytes play a key
pathogenic role by acting as a major producer of type I IFNs (5). Human monocytes express TLR9 and respond to CpG
(13,43). We observed that C1q or
anti–LAIR-1 antibody inhibited CpG-
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Figure 4. LAIR-1 engagement induces an interaction between LAIR-1 and SHP-1, but CpG stimulation induces an interaction of Hck with
LAIR-1. (A) Human monocytes were stimulated with CpG, C1q, CpG plus C1q or CpG plus anti–LAIR-1 antibody for 30 min. Cell lysates
were immunoprecipitated with anti–LAIR-1 antibody, and LAIR-1 binding proteins were analyzed by Western blot. Data are representative
of three independent experiments. (B) Cells were stimulated for the indicated time, and the same experiment as in (A) was performed.
Numbers in blots represent density, and relative bindings were calculated by the ratio for the immune-precipitated LAIR-1. Experiments
were repeated three times, and representative data are shown.

mediated nuclear translocation of IRF3
and IRF5 and phosphorylation of IkBα.
The fact that the suppression of CpGmediated activation of monocytes by
C1q was reversed by LAIR-1–specific
siRNA demonstrated that the suppressive effects of C1q are LAIR-1 dependent. Transfection of monocytes with
LAIR-1 siRNA led to higher baseline levels of cytokine transcription, demonstrating a role for LAIR-1 in monocyte
homeostasis. Moreover, CpG did not increase cytokine expression in monocytes

lacking LAIR-1 expression, suggesting
that CpG stimulation blocks the constitutive inhibitory function of LAIR-1. Our
findings demonstrate a contribution of
C1q deficiency to SLE that is independent of the role of C1q in clearance of
apoptotic debris.
To identify the proteins that interact
with LAIR-1 after TLR9 activation with
or without LAIR-1 engagement, we performed immunoprecipitation studies by
using anti–LAIR-1 antibody. Csk constitutively associates with LAIR-1. We ob-

served an increased association of inactive Hck with LAIR-1 upon CpG treatment; presumably Csk phosphorylates
the C-terminal tyrosine of Hck to produce the inactive form that we observed.
We propose that CpG activates Csk leading to phosphorylation of Y522 and inactivation of Hck on LAIR-1. Binding sites
have been identified on LAIR-1 for Hck
(Y251) (VTYAQL) and Csk (Y281)
(ITYAAV). We also observed increased
phosphorylation of the LAIR-1 ITIM motifs after CpG exposure, but phosphory-
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Figure 5. LAIR-1 engagement induces the tyrosine phosphorylation. The state of LAIR-1
phosphorylation was measured by a proteome profile array–human phospho-immunoreceptor assay. Whole cell extracts from untreated (Utx), CpG, CpG plus C1q or CpG plus
anti–LAIR-1 antibody were analyzed. The experiment was repeated three times, and representative data are shown. Relative quantification for the phosphorylation of LAIR-1 was
normalized to control spots.

lation was even greater in the presence of
C1q or anti–LAIR-1 antibody. We propose that C1q engages LAIR-1, causing
Hck to be activated, perhaps auto-catalytically, and leading to the phosphorylation of the ITIM motifs of LAIR-1. This
step permits binding to SHP-1. SHP-1
binds to both ITIM motifs when they are
phosphorylated. In this way, C1q and
LAIR-1 mediate an inhibitory pathway
modulating TLR9 activation (Figure 6).
LAIR-1 mediates partial inhibition in a
ligand-independent fashion. There may
be some SHP-1 associated with LAIR-1
in the resting state. This association is
not detected in our coimmunoprecipitation studies and is eliminated when CpG
is present. After LAIR-1 engagement by
C1q, phosphorylated LAIR-1 recruits
SHP-1 and induces the phosphatase activity of SHP-1. SHP-1 dephosphorylates
the activating tyrosine residues of SFKs,
as well as various other intracellular tyrosine phosphorylation substrates.
IFNs are key mediators of host defense
to viral and bacterial infection. They are
also thought to be involved in the pathogenesis of SLE (17,20,44,45). Patients
treated with IFN for hepatitis C infection
develop anti-nuclear antibodies or overt
SLE (46). Serum levels of IFN correlate
with disease activity in SLE. We demonstrate that C1q and LAIR-1 signaling

suppresses the activation of IRFs, and
this mechanism regulates the transcription of multiple cytokines upon CpG
stimulation in human monocytes.

CONCLUSION
An absence of C1q has been shown to
lead to enhanced IFN production by both
human and mouse pDCs (39,41). We also
have tested whether C1q inhibits
myeloid cell activation by other PAMPs
such as LPS or high-mobility group protein B1 (HMGB1). Interestingly, C1q also
has a suppressive function in the
HMGB1-mediated production of IFN
(unpublished data). Kanakoudi-Tskalidou et al. (7) showed that mean serum
levels of HMGB1 are positively correlated with levels of IFNα and the expression of LAIR-1 on pDCs of SLE patients
is significantly lower than its expression
on pDCs of healthy controls (47). These
findings suggest that C1q/LAIR-1 signaling mediates a major inhibitory pathway for the innate immune response.
Manipulating LAIR-1 may be a strategy
for regulating inflammation and, specifically, disease activity in SLE. Notably, we
also have observed that the C1q collagen

Figure 6. Model demonstrating how LAIR-1 contributes to immune tolerance. (A) In the
resting state, Csk constitutively associates with LAIR-1. (B) When LAIR-1 is engaged in the
presence of C1q, Hck phosphorylates the ITIMs on LAIR-1. Phosphorylated LAIR-1 recruits
SHP-1 and induces the phosphatase activity of SHP-1. SHP-1 mediates the inhibition of
monocytes by dephosphorylating the activating tyrosine residues of various intracellular
tyrosine-phosphorylation substrates and by inhibiting nuclear translocation of IRFs or NF-κB
resulting in cytokine production.
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tail, which engages LAIR-1, inhibits TLR
signaling. A recent report showed that
collagenous domains of C-type lectin
surfactant protein-D (SP-D) bind to
LAIR-1 and regulate FcαR-mediated reactive oxygen production in neutrophils
(48). These results suggest that LAIR-1
engagement by collagen-like domains
may be a therapeutic strategy for controlling inflammation in SLE and inflammatory conditions.
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